vs

Side-by-side financial comparison of AMREP CORP. (AXR) and Voyager Therapeutics, Inc. (VYGR). Click either name above to swap in a different company.

Voyager Therapeutics, Inc. is the larger business by last-quarter revenue ($15.3M vs $14.6M, roughly 1.1× AMREP CORP.). On growth, Voyager Therapeutics, Inc. posted the faster year-over-year revenue change (144.3% vs 93.8%). AMREP CORP. produced more free cash flow last quarter ($5.4M vs $-135.1M). Over the past eight quarters, Voyager Therapeutics, Inc.'s revenue compounded faster (-11.4% CAGR vs -13.6%).

AMREP Corporation is a real estate and media services company based in Princeton, New Jersey, in the United States. It was founded in 1961 as The American Realty and Petroleum Corporation.

Voyager Therapeutics, Inc. is a clinical-stage biotechnology firm focused on developing AAV gene therapies for severe neurological diseases including Parkinson's, ALS, and rare monogenic CNS disorders. It operates mainly in the U.S., partnering with global biopharma companies to advance its treatment pipeline for underserved patient populations.

AXR vs VYGR — Head-to-Head

Bigger by revenue
VYGR
VYGR
1.1× larger
VYGR
$15.3M
$14.6M
AXR
Growing faster (revenue YoY)
VYGR
VYGR
+50.5% gap
VYGR
144.3%
93.8%
AXR
More free cash flow
AXR
AXR
$140.4M more FCF
AXR
$5.4M
$-135.1M
VYGR
Faster 2-yr revenue CAGR
VYGR
VYGR
Annualised
VYGR
-11.4%
-13.6%
AXR

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
AXR
AXR
VYGR
VYGR
Revenue
$14.6M
$15.3M
Net Profit
$3.1M
Gross Margin
Operating Margin
20.6%
Net Margin
21.6%
Revenue YoY
93.8%
144.3%
Net Profit YoY
338.9%
20.5%
EPS (diluted)
$0.58

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXR
AXR
VYGR
VYGR
Q1 26
$14.6M
Q4 25
$9.4M
$15.3M
Q3 25
$17.9M
$13.4M
Q2 25
$11.2M
$5.2M
Q1 25
$7.5M
$6.5M
Q4 24
$11.9M
$6.3M
Q3 24
$19.1M
$24.6M
Q2 24
$19.5M
$29.6M
Net Profit
AXR
AXR
VYGR
VYGR
Q1 26
$3.1M
Q4 25
$1.2M
Q3 25
$4.7M
$-27.9M
Q2 25
$3.9M
$-33.4M
Q1 25
$717.0K
$-31.0M
Q4 24
$4.0M
Q3 24
$4.1M
$-9.0M
Q2 24
$4.1M
$-10.1M
Operating Margin
AXR
AXR
VYGR
VYGR
Q1 26
20.6%
Q4 25
11.9%
Q3 25
34.4%
-228.9%
Q2 25
31.7%
-704.3%
Q1 25
5.7%
-536.0%
Q4 24
26.4%
Q3 24
26.1%
-56.0%
Q2 24
23.9%
-50.8%
Net Margin
AXR
AXR
VYGR
VYGR
Q1 26
21.6%
Q4 25
12.8%
Q3 25
26.3%
-208.7%
Q2 25
34.8%
-642.0%
Q1 25
9.5%
-479.2%
Q4 24
33.9%
Q3 24
21.3%
-36.7%
Q2 24
21.2%
-34.3%
EPS (diluted)
AXR
AXR
VYGR
VYGR
Q1 26
$0.58
Q4 25
$0.22
Q3 25
$0.87
$-0.47
Q2 25
$0.73
$-0.57
Q1 25
$0.13
$-0.53
Q4 24
$0.75
Q3 24
$0.76
$-0.16
Q2 24
$0.77
$-0.18

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXR
AXR
VYGR
VYGR
Cash + ST InvestmentsLiquidity on hand
$50.0M
$196.4M
Total DebtLower is stronger
$21.0K
Stockholders' EquityBook value
$139.4M
$196.1M
Total Assets
$143.9M
$252.3M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXR
AXR
VYGR
VYGR
Q1 26
$50.0M
Q4 25
$44.6M
$196.4M
Q3 25
$48.9M
$208.9M
Q2 25
$39.5M
$215.6M
Q1 25
$36.9M
$236.0M
Q4 24
$40.1M
$266.7M
Q3 24
$40.4M
$345.4M
Q2 24
$29.7M
$371.0M
Total Debt
AXR
AXR
VYGR
VYGR
Q1 26
$21.0K
Q4 25
$23.0K
Q3 25
$25.0K
Q2 25
$26.0K
Q1 25
$29.0K
Q4 24
$32.0K
Q3 24
$34.0K
Q2 24
$35.0K
Stockholders' Equity
AXR
AXR
VYGR
VYGR
Q1 26
$139.4M
Q4 25
$136.0M
$196.1M
Q3 25
$134.7M
$219.8M
Q2 25
$130.0M
$243.9M
Q1 25
$126.0M
$272.7M
Q4 24
$125.1M
$299.8M
Q3 24
$122.2M
$330.3M
Q2 24
$118.0M
$335.4M
Total Assets
AXR
AXR
VYGR
VYGR
Q1 26
$143.9M
Q4 25
$140.1M
$252.3M
Q3 25
$140.7M
$288.3M
Q2 25
$133.8M
$322.1M
Q1 25
$128.9M
$353.2M
Q4 24
$129.1M
$393.1M
Q3 24
$127.0M
$426.0M
Q2 24
$122.8M
$436.2M
Debt / Equity
AXR
AXR
VYGR
VYGR
Q1 26
0.00×
Q4 25
0.00×
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXR
AXR
VYGR
VYGR
Operating Cash FlowLast quarter
$5.4M
$-132.5M
Free Cash FlowOCF − Capex
$5.4M
$-135.1M
FCF MarginFCF / Revenue
37.0%
-880.7%
Capex IntensityCapex / Revenue
0.1%
16.9%
Cash ConversionOCF / Net Profit
1.72×
TTM Free Cash FlowTrailing 4 quarters
$20.2M
$-239.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXR
AXR
VYGR
VYGR
Q1 26
$5.4M
Q4 25
$-4.3M
$-132.5M
Q3 25
$9.5M
$-31.0M
Q2 25
$10.2M
$-33.3M
Q1 25
$-3.2M
$-37.9M
Q4 24
$-182.0K
$-15.3M
Q3 24
$10.7M
$-28.0M
Q2 24
$10.7M
$-31.6M
Free Cash Flow
AXR
AXR
VYGR
VYGR
Q1 26
$5.4M
Q4 25
$-4.3M
$-135.1M
Q3 25
$9.5M
$-31.3M
Q2 25
$9.7M
$-34.4M
Q1 25
$-3.3M
$-38.6M
Q4 24
$-268.0K
$-18.8M
Q3 24
$10.7M
$-28.2M
Q2 24
$10.3M
$-32.5M
FCF Margin
AXR
AXR
VYGR
VYGR
Q1 26
37.0%
Q4 25
-45.9%
-880.7%
Q3 25
53.2%
-233.9%
Q2 25
86.4%
-660.9%
Q1 25
-43.4%
-595.6%
Q4 24
-2.3%
-300.0%
Q3 24
55.8%
-114.6%
Q2 24
52.5%
-110.0%
Capex Intensity
AXR
AXR
VYGR
VYGR
Q1 26
0.1%
Q4 25
0.6%
16.9%
Q3 25
0.1%
1.5%
Q2 25
5.2%
21.3%
Q1 25
0.3%
10.2%
Q4 24
0.7%
56.1%
Q3 24
0.2%
1.0%
Q2 24
2.3%
3.3%
Cash Conversion
AXR
AXR
VYGR
VYGR
Q1 26
1.72×
Q4 25
-3.54×
Q3 25
2.03×
Q2 25
2.63×
Q1 25
-4.51×
Q4 24
-0.05×
Q3 24
2.63×
Q2 24
2.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons